Xcelerate Inc Stock Price, News & Analysis

Xcelerate, Inc. (OTC pink sheets: XCRT) announced on January 3, 2022, that it has acquired a 51% stake in AfiyaSasa Africa, LLC, a medical technology and virtual health company. This acquisition aims to enhance healthcare access in developing regions by utilizing AI and Augmented Reality to connect patients with physicians remotely. The ASA system facilitates initial check-ins and triage through mobile devices, utilizing medical devices linked to phones for effective telemedicine. This partnership with ASA, co-founded by Dr. Dilan Ellegala, is expected to improve healthcare delivery for millions in Africa.

Xcelerate, Inc. (OTC: XCRT) has signed a Definitive Memorandum of Understanding with HS Pharmaceuticals, LLC to acquire 100% of its membership interests and a 51% interest in HS Cosmetics, Inc. This agreement includes provisions for drafting an Acquisition Agreement with a pre-determined valuation and capital raising efforts to support HS Pharmaceuticals' intellectual property development and HS Cosmetics' marketing strategy initiated in April 2021. CEO Michael O'Shea noted collaboration with Network1 Financial to facilitate these financial activities.

Xcelerate, Inc. (OTC Pink Sheets: XCRT) announced the completion of its Consolidated Annual Financial Statements audit for FY 2019 and FY 2020, conducted by BF Borgers CPA PC, a PCAOB registered firm. This achievement is a significant step towards the company's objective to uplist to OTCQB or QX, eventually aiming for a national exchange. The company focuses on acquiring and commercializing medical innovations, combining them with early-stage med tech enterprises.

Xcelerate (OTC Pink Sheets: XCRT) has engaged BF Borgers CPA PC for auditing its financial statements for the fiscal years ending December 31, 2019, and 2020. This move aligns with the company's goal to enhance shareholder value, according to CEO Michael O'Shea. Additionally, the management is exploring potential acquisition candidates, aiming for future growth. While no agreements are in place yet, there is optimism about success. Xcelerate plans to raise funds for business capital and pursue uplisting to OTCQB or QX, with hopes of eventually achieving a NASDAQ listing.

Xcelerate, Inc. (OTC: XCRT) has entered into two investment banking agreements with a prominent New York-based firm to facilitate acquisition financing. This firm, established in the late 1980s, manages over $2.8 billion in retail accounts. Xcelerate will leverage this partnership to support its aggressive acquisition strategy as it identifies potential targets. The company's CEO, Michael O'Shea, expressed confidence that these agreements validate their business plan and will accelerate growth.

Xcelerate, Inc. (OTC: XCRT) announced that Nobel Prize winner Dr. Barry Marshall discussed the company's mission to enhance medical technology during a global broadcast on ticker NEWS. Dr. Marshall, who serves on Xcelerate's Advisory Board, emphasized the benefits of working with an American public company, particularly in funding. He aims to identify investment opportunities in Australia for Xcelerate. CEO Michael O'Shea highlighted Dr. Marshall's contributions and the importance of increasing public awareness to support investment and medical communities.

Xcelerate, Inc. (OTC pink sheets: XCRT) announced signing a non-binding letter of intent (LOI) to explore a business combination with HS Pharmaceuticals, LLC, based in Greenville, SC. HS Pharmaceuticals has a platform of patented technologies focusing on immunotherapy alternatives and infection treatment. Xcelerate aims to leverage HS’s research and intellectual property through due diligence led by its team of clinicians and researchers. This strategic move underscores Xcelerate's commitment to innovative acquisitions in early-stage medical technology.

Xcelerate, a leader in early-stage medical technology, announced on May 3, 2021, the removal of the 'Yield' sign from its stock symbol by OTC Markets, achieving 'Pink Current Reporting' status. This change enhances corporate transparency and allows investors better access to company information. CEO Michael O'Shea expressed enthusiasm for this milestone, emphasizing ongoing efforts to maintain compliance and improve corporate standing. Additionally, the company is exploring innovative acquisitions in the patent and engineering sectors to further its growth.

Xcelerate, Inc. (OTC: XCRT) has launched a new website, www.xcelerate.global, highlighting its innovative role in integrating advanced engineering solutions with MedTech and clinical care. The website aims to communicate the company's mission, progress, and potential within the MedTech sector, serving as a platform for updates and news. CEO Michael O'Shea emphasized that the global domain reflects the company’s aspirations for international growth and collaboration. Xcelerate focuses on acquiring patents and engineering technologies and is committed to advancing early-stage medical technologies.